Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $1,282.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on REGN. Argus boosted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a report on Tuesday, June 25th. TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a research note on Tuesday, July 23rd. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research note on Thursday, July 11th. Barclays upped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an overweight rating in a research note on Friday, August 2nd. Finally, StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $1,111.30.

Regeneron Pharmaceuticals Trading Down 0.4 %

REGN opened at $1,145.03 on Tuesday. Regeneron Pharmaceuticals has a 12 month low of $769.19 and a 12 month high of $1,211.20. The stock has a market capitalization of $126.23 billion, a price-to-earnings ratio of 33.83, a PEG ratio of 3.93 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business has a fifty day moving average price of $1,131.75 and a 200 day moving average price of $1,031.74.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.79 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock worth $11,498,705 in the last quarter. Company insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Sachetta LLC grew its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $26,000. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.